Cargando…

Dysplastic Nodules with Glypican-3 Positive Immunostaining: A Risk for Early Hepatocellular Carcinoma

Glypican-3 (GPC3) has been reported to be a novel serum and histochemical marker for HCC. The positivity or negativity for GPC3 in hepatic precancerous lesions, such as dysplastic nodules (DN), has also been described. Moreover, our previous studies have demonstrated that some DN in liver cirrhosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Li, Wei, Long-Xiao, Ren, Pin, Zhang, Wen-Dong, Liu, Xiao-Yan, Han, Xiu-Juan, Yao, Li, Zhu, Shao-Jun, Lan, Miao, Li, Yan-Hong, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909016/ https://www.ncbi.nlm.nih.gov/pubmed/24498024 http://dx.doi.org/10.1371/journal.pone.0087120

Ejemplares similares

Promoter Methylation of E-cadherin in Hepatocellular Carcinomas and Dysplastic Nodules
por: Kwon, Ghee Young, et al.
Publicado: (2005)

Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma
por: Joung, Je-Gun, et al.
Publicado: (2016)

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
por: Xiao, Wei-Kai, et al.
Publicado: (2014)

Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature
por: Peng, Chengyuan, et al.
Publicado: (2016)

Early hepatocellular carcinoma developed within dysplastic nodule as nodule-within-nodule appearance: Case report with literature review
por: Aassouani, Farid, et al.
Publicado: (2022)

Diagnostic value of clusterin immunostaining in hepatocellular carcinoma
por: Li, Yuan, et al.
Publicado: (2020)

Reduced tumor stiffness quantified by tomoelastography as a predicative marker for glypican-3-positive hepatocellular carcinoma
por: Wang, Yihuan, et al.
Publicado: (2022)

A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values
por: Jin, Guang-Zhi, et al.
Publicado: (2013)

The stromal morphological changes for differential diagnosis of uninodular high-grade dysplastic nodule and well-differentiated small hepatocellular carcinoma
por: Feng, Long-Hai, et al.
Publicado: (2017)

Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma
por: Rizzo, Francesca, et al.
Publicado: (2016)

Detection of Endogenous Iron Reduction during Hepatocarcinogenesis at Susceptibility-Weighted MR Imaging: Value for Characterization of Hepatocellular Carcinoma and Dysplastic Nodule in Cirrhotic Liver
por: Li, Ruo-kun, et al.
Publicado: (2015)

Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging
por: Chen, Yidi, et al.
Publicado: (2022)

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas
por: El-Saadany, Sherif, et al.
Publicado: (2018)

Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
por: Nishida, Takahiro, et al.
Publicado: (2019)

Computed Tomography during Arteriography and Arterial Portography in Small Hepatocellular Carcinoma and Dysplastic Nodule: A Prospective Study
por: Mikami, Shinichi, et al.
Publicado: (2000)

Radiomics nomogram for prediction of glypican-3 positive hepatocellular carcinoma based on hepatobiliary phase imaging
por: Zhang, Ning, et al.
Publicado: (2023)

Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma
por: Wang, Congrong, et al.
Publicado: (2020)

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
por: Chen, I-Pei, et al.
Publicado: (2013)

Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis
por: Gazelakis, Kathryn, et al.
Publicado: (2021)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe
por: Han, Hai-Hao, et al.
Publicado: (2018)

Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma
por: Zhang, Yi-Fan, et al.
Publicado: (2016)

The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer
por: LI, YAN, et al.
Publicado: (2013)

Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma
por: Wang, Jian-Yao, et al.
Publicado: (2021)

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
por: Guo, Meng, et al.
Publicado: (2020)

Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study
por: Sato, Tsunenobu, et al.
Publicado: (2015)

Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis
por: Zhang, Jian, et al.
Publicado: (2018)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
por: Ma, Haili, et al.
Publicado: (2017)

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2016)

Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
por: Bell, Meghan M., et al.
Publicado: (2020)

Delta-radiomics models based on multi-phase contrast-enhanced magnetic resonance imaging can preoperatively predict glypican-3-positive hepatocellular carcinoma
por: Han, Zewen, et al.
Publicado: (2023)

The so-called dysplastic nevus is not dysplastic at all
por: Madan, Raman, et al.
Publicado: (2013)

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
por: Liu, Quan, et al.
Publicado: (2017)

Qualitative analysis of small (≤2 cm) regenerative nodules, dysplastic nodules and well-differentiated HCCs with gadoxetic acid MRI
por: Di Martino, Michele, et al.
Publicado: (2016)

Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas
por: Nie, Jun‐Hua, et al.
Publicado: (2022)

Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma
por: Liu, Peijun, et al.
Publicado: (2023)

Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma
por: Lee, Hyun Jung, et al.
Publicado: (2014)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_in4aimf59qe1g2a7dkgsm4ctvt